Drug intelligence / Profile preview

TGFBI gene therapy

Development stage: Preclinical
Lead developer: GenEditBio
Modality: Gene Therapies
Administration: Ophthalmic

Overview

TGFBI gene therapy is a therapeutic approach under clinical investigation for the treatment of corneal dystrophy, specifically TGFBI Stromal Corneal Dystrophy. This gene therapy aims to target the TGFBI gene, which is known to be involved in the pathology of this corneal disorder. It is being studied as an adjuvant to phototherapeutic keratectomy (PTK).

Targets

TGFBI (Transforming growth factor-beta-induced protein ig-h3)

Beyond the preview

Go deeper on TGFBI gene therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TGFBI gene therapy.

Explore the full profile